Geraghty James A
- SEC CIK
- 0001239746
No open-market purchases or sales filed in the past year.
Current role at each company
- FULC Fulcrum Therapeutics, Inc.Directoras of Jul 2, 2026
- VYGR Voyager Therapeutics, Inc.Directoras of Jun 11, 2026
- PVLA Palvella Therapeutics, Inc.Directoras of Dec 12, 2024
- ORTX Orchard Therapeutics plcDirectoras of Jan 24, 2024
- ACGN Aceragen, Inc.Directoras of Jun 27, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Geraghty James A as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
PVLA Palvella Therapeutics, Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 28, 2024 (view filing) | Aug 7 | 82 daysLate | Geraghty James ADirector | PPurchaseSeries F Preferred Stock, par value $0.001 per share | +1 | $1.00 | +$1 | New position1 after |